Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delamanid in Pediatric MDR-TB
NCT01859923Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2013
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of delamanid in multidrug-resistant tuberculosis (MDR-TB), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jul 2013; status: completed.
02
Drugs
delamanid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT01859923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01859923.